Quarterly net profit surge and chronic portfolio momentum
Mankind Pharma released its financial results for the second quarter of fiscal year 2026-2027 on Monday afternoon, reporting outstanding operational momentum across its core formulations division. Consolidated net profit escalated from 5.12 billion rupees in the corresponding prior-year quarter to 7.11 billion rupees (approximately $74.7 million), reflecting a growth rate exceeding 39%.
The earnings acceleration was anchored by high-margin chronic therapy categories, with the cardiac pharmaceutical portfolio expanding 19% year-on-year and anti-diabetes treatments climbing 16%.












